Only FDA device specifically approved for ALS patients

For patients with ALS, the FDA approved NeuRx DPS® delays the need for mechanical ventilation and tracheostomy. It has also been shown to help condition the diaphragm muscle to improve fatigue resistance.

Learn More >

Our breakthrough diaphragm pacing system for spinal cord injuries

Our FDA approved NeuRx DPS® is specifically designed to decrease the reliance on mechanical ventilators for patients with spinal cord injuries.

Learn More >

What NeuRx DPS® Patients Are Saying

I use the DPS 8-12 hours per night with my Trilogy device 4-6 hours per night. The DPS is very easy to operate. I would recommend the Diaphragm Pacing System to any ALS patient that is a candidate.- Michael Gaither
This system is opening up a new world to me. Without having tubes on my chest and not hearing the constant noise from the ventilator, I feel much more like a person and less like a machine. I am looking forward to the changing seasons and smelling the new plants in spring and outdoor grills in summer.- Joel Vander Molen
Living with ALS is difficult so when something helps it is such an amazing feeling. Since having the diaphragm pacer I feel my breathing has improved and I feel better. Not only this, even more it also offers hope to stay off the trach longer.- Martha Bryant
The competent and compassionate service that I have received from this company is exemplary. Any time that I have a question or a concern, one of Synapse's representatives is always readily available to assist me, even if that means driving to Harrisburg to meet with me. Thank you, Synapse, for giving me my life back.- Nicholas Essis

Synapse Biomedical and Case Western Reserve University Announce Collaboration to Commercialize Advanced Neurostimulation Technology

With the support of a $3 million Ohio Third Frontier Innovation Platform Program grant, Synapse Biomedical Inc. will lead the commercialization of third.. Read More →

U.S. Diaphragm Pacing Study in ALS Continues Enrollment

The Post Approval Study’s (PAS) Interim Data Showed Device Safety and Median Survival Post-Implant of 20.9 months Synapse Biomedical Inc. reported today that.. Read More →

U.S. ALS Diaphragm Pacing Study Showing Safety and Benefit Trend Is Suspended Due to Slow Recruitment

Synapse Biomedical Inc. received word that the Northeast ALS Consortium (NEALS) Data and Safety Monitoring Board (DSMB) has recommended suspending new enrollment of.. Read More →